Latest news with #TazeenAhmad
Yahoo
2 days ago
- Business
- Yahoo
Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), while lowering the price target from $80 to $79. The firm held its positive outlook even after the recent challenge from the FDA's complete response letter for UX111 in Sanfilippo syndrome. The CRL was focused on specific chemistry, manufacturing, and controls issues. Importantly, the clinical data for UX111 was not questioned; however, the approval is still achievable once the CMC issues are resolved. A research team in a laboratory peering through microscopes at a biologic product. The analyst noted that the company is responding quickly and plans to address the CMC concerns and resubmit its Biologics License Application in the coming months. The analyst is also optimistic due to Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) robust pipeline. The company has promising programs for conditions like osteogenesis imperfecta and Angelman syndrome. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops treatments for rare and ultra-rare genetic diseases. They focus on biologics, small molecules, gene therapy, and nucleic acid products. While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
01-07-2025
- Business
- Business Insider
BioCryst price target raised to $15 from $13 at BofA
BofA analyst Tazeen Ahmad raised the firm's price target on BioCryst (BCRX) to $15 from $13 and keeps a Buy rating on the shares after the company announced an agreement to sell the European Orladeyo business to Neopharmed Gentili for up to $264M. The firm is 'encouraged' by the deal given the majority of Orladeyo revenues are realized in the U.S. and it provides clear line of sight for settling outstanding debt, the analyst tells investors. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
30-06-2025
- Business
- Yahoo
BofA Remains Bullish on Argenx (ARGX) With a Buy Rating and $804 PT
Argenx SE (NASDAQ:ARGX) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 16, Bank of America Securities analyst Tazeen Ahmad maintained a bullish stance on Argenx SE (NASDAQ:ARGX), giving it a Buy rating with an $804 price target. The analyst based the optimistic rating on the promising growth prospects of the company's Vyvgart, especially in the treatment of CIDP and gMG. A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases. The expert neurologist consulted in the report stated that Vyvgart has a suitable efficacy and a favorable safety profile, which is either comparable to or superior to that of the present treatments, such as IVIg. This factor has resulted in a notable uptake, especially in patients who have not responded well to IVIg. The analyst expects Vyvgart to capture around half the market share in CIDP over time, contributing to the positive rating for Argenx SE (NASDAQ:ARGX). Ahmad further stated that Vyvgart's role in the treatment of gMG is expanding, as it is becoming the leading biologic choice because of its safety and efficacy. The expected approval of the pre-filled syringe (PFS) may further support Vyvgart's adoption, especially in large hospitals and rural areas with challenging infusion coordination. Argenx SE (NASDAQ:ARGX) is a global immunology company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China. While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-06-2025
- Business
- Yahoo
BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy Rating
Ascendis Pharma A/S (NASDAQ:ASND) is . On June 9, BofA analyst Tazeen Ahmad reiterated a 'Buy' rating on the stock and raised the price target to $216 from $201. A biopharmaceutical scientist wearing a lab coat, examining a microscope of cells. The adjustment follows the company delivering positive interim results from the Phase 2 COACH trial. The trial sought to ascertain the effectiveness of a combination treatment QW TransCon CNP and QW TransCon HGH in children with Achondroplasia (ACH). Trial results indicated significant annualized growth velocity benefits with the combination treatment. According to the analyst, the trial results are favorable and likely to strengthen the company's prospects of capturing market share once the treatment enters the market. Following the positive trial results, Ascendis plans to release 52-week data from the COACH trial in the fourth quarter. Likewise, the US Food and Drug Administration (FDA) has accepted the company's New Drug Application for TransCon, its candidate drug for treating achondroplasia. Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and commercializes new therapies for unmet medical needs, particularly in endocrinology and oncology. It leverages a proprietary TransCon technology platform to create innovative and potentially best-in-class therapies. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Business Insider
05-06-2025
- Business
- Business Insider
ACADIA Pharmaceuticals (ACAD) Gets a Hold from Bank of America Securities
In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $23.00. The company's shares closed yesterday at $21.77. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Ahmad is an analyst with an average return of -1.3% and a 49.49% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Incyte, Sarepta Therapeutics, and PTC Therapeutics. In addition to Bank of America Securities, ACADIA Pharmaceuticals also received a Hold from Morgan Stanley's Sean Laaman in a report issued on May 20. However, on the same day, Deutsche Bank upgraded ACADIA Pharmaceuticals (NASDAQ: ACAD) to a Buy. ACAD market cap is currently $3.59B and has a P/E ratio of 16.00. Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACAD in relation to earlier this year. Most recently, in March 2025, ELIZABETH A. GAROFALO, a Director at ACAD sold 4,919.00 shares for a total of $89,673.37.
